Medtronic: The CAS Catalyst Can Close A 27% Peer Discount

Medtronic is rated a 'Buy,' favored for its attractive valuation and potential upside from its CAS segment despite recent underperformance. CAS, now 5-6% of revenue, is annualizing above $2B and could reach $3B in a few years if execution remains strong. Guidance targets 6.75%-7.25% organic growth and $5.90-$6.00 EPS, but calendar effects and MiniMed separation timing are key variables. MDT trades at a 25-27% P/E discount to peers, yields 3.1%, and is best accumulated on weakness as the turnaround story progresses.

Medtronic (MDT) has lagged the broader market (SPY) YTD with a total return that is roughly flat versus ~13.4% on the SPY. The stock has largely rebounded from a sell-off that ended in June. Slow earnings growth and